一分钟看懂
这是一项关于淋巴瘤的II 期研究，登记的药物或干预包括Ibrutinib；Rituximab；Gemcitabine；Dexamethasone；Cisplatin；Mesna；Cyclophosphamide；Etoposide；G-CSF；Selinexor，当前状态为研究进行中，已停止招募。登记地点显示中国Calgary、Edmonton、Vancouver、Winnipeg等城市有研究中心记录。是否仍有名额以及是否值得进一步询问，需要向研究中心确认。
药物或干预
Ibrutinib；Rituximab；Gemcitabine；Dexamethasone；Cisplatin；Mesna；Cyclophosphamide；Etoposide；G-CSF；Selinexor · II 期
中国哪些地方有记录
以下地点来自登记信息，不代表此刻仍有名额；请向研究中心确认最新情况。
- Arthur J.E. Child Comprehensive Cancer Centre · Calgary
- Cross Cancer Institute · Edmonton
- BCCA - Vancouver · Vancouver
- CancerCare Manitoba · Winnipeg
- QEII Health Sciences Centre · Halifax
- Kingston Health Sciences Centre · Kingston
- Ottawa Hospital Research Institute · Ottawa
- University Health Network · Toronto
- CHUM-Centre Hospitalier de l'Universite de Montreal · Montreal
- CHU de Quebec-Hopital l'Enfant-Jesus (HEJ) · Québec
- Allan Blair Cancer Centre · Regina
公开的入选条件
- * Patients with histologic diagnosis for one of the following histologies according to the World Health Organization: documented at initial diagnosis or at relapse:
- Diffuse large cell lymphoma, B-cell (includes primary mediastinal B-cell lymphoma, T-cell rich B-cell lymphoma);
- Previous indolent lymphoma (follicular lymphoma, marginal zone lymphoma, including extranodal MALT lymphoma, lymphoplasmacytoid lymphoma) with transformation to diffuse large B-cell lymphoma at most recent relapse (biopsy proof of transformation is mandatory);
- Unclassifiable B-cell lymphoma with indeterminate features between diffuse large B-cell lymphoma and Burkitt lymphoma.
- * Biopsy proof of disease at initial diagnosis is mandatory. A repeat biopsy in primary refractory disease is preferred but not mandatory to confirm progressive disease. A biopsy at relapse is preferred but not mandatory. Participating centres must designate a
- * Patients must be CD20+ in order to be eligible for the study.
- * Clinically and/or radiologically measurable disease (one site bidimensionally measurable). Measurements/ evaluations must be done within 28 days prior to randomization.
- * Prior FDG-PET scan, if done at baseline, must be positive (known FDG-avid lymphoma)
联系前需要确认
请继续确认中心是否启动、疾病分型、既往治疗、检查费用和知情同意安排。
查看登记信息
登记号：NCT02436707；登记信息更新于 2026-09-17。